Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVOR cardiovascular outcomes trial of saxagliptin in type 2 diabetes mellitus
2009-017358-10Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin added to background therapy with Placebo added to background therapy (2 arms). Primary endpoint: Primary efficacy and safety outcome. Started Feb 2010; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-017358-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017358-10.